Is suramin available in Australia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Suramin Availability in Australia

Suramin is not commercially available in Australia through standard pharmaceutical channels, but can potentially be accessed through special access schemes for the treatment of first-stage rhodesiense human African trypanosomiasis (sleeping sickness).

Current Status and Access Pathways

  • Suramin remains an approved treatment for first-stage rhodesiense HAT in children younger than 6 years or with bodyweight less than 20 kg, as fexinidazole has not been studied in this population 1.

  • In non-endemic countries like Australia, suramin would need to be obtained through:

    • Special Access Scheme (Category A or B) from the Therapeutic Goods Administration (TGA)
    • Emergency importation protocols for rare tropical diseases
    • Direct contact with WHO or specialized tropical disease centers
  • The 2025 WHO guidelines note that pentamidine is more likely to be available than suramin in non-endemic countries, as pentamidine is also used for Pneumocystis jirovecii pneumonia treatment 1.

Clinical Context for Use

For patients requiring suramin in Australia:

  • First-stage rhodesiense HAT is the primary indication where suramin remains necessary, particularly for young children 1.

  • When oral fexinidazole absorption is uncertain (critical illness, inability to swallow), suramin may be preferred for first-stage disease 1.

  • Immediate treatment is critical given the rapid progression of rhodesiense HAT; if suramin is unavailable, interim pentamidine treatment should be initiated while arranging access to first-line drugs 1.

Important Caveats

  • Suramin has been replaced by fexinidazole as first-line therapy for most patients with rhodesiense HAT (age ≥6 years, weight ≥20 kg) 1.

  • The drug has significant toxicity, including dose-dependent polyneuropathy, and requires careful monitoring 2.

  • Suramin is not registered for any other indication in Australia, despite historical research into cancer and other conditions 3, 4, 5.

For suspected HAT cases in Australia, immediate consultation with infectious disease specialists and tropical medicine centers is essential to arrange appropriate drug access and treatment.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Suramin-induced neuropathy in an animal model.

Journal of the neurological sciences, 2001

Research

100 Years of Suramin.

Antimicrobial agents and chemotherapy, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.